Comprehensive Transcriptomic and Immune Profiling Identifies Unique Mitochondrial and Immune Signatures in COVID-19 Related ARDS Necessitating Invasive Mechanical Ventilation

Category	Detail
Condition	COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
Key Mechanisms	Mitochondrial dysfunction, cytokine storm, immune exhaustion
Target Population	Patients with severe COVID-19 requiring invasive mechanical ventilation
Care Setting	Hospitalized patients in intensive care units

IMV patients had longer hospital and ICU stays compared to non-IMV patients.
28-day mortality was significantly higher in the IMV group (45.5% vs. 12.0%).
Distinct transcriptomic profiles were identified in IMV patients, including downregulation of mitochondrial gene MTARC2.
Elevated plasma IL-6, IL-8, and IL-10 levels were observed in IMV patients, with IL-10 showing strong predictive value.
Higher percentage of CD57− NK cells was found at baseline in the non-IMV group.

Utilize transcriptomic and immune profiling to distinguish between IMV and non-IMV patients.

Monitor cytokine levels, particularly IL-10, as potential prognostic biomarkers.

Assess hospital and ICU stay duration and 28-day mortality rates in patients with ARDS.

Patients requiring IMV are at higher risk for prolonged hospitalization and increased mortality.

Adults (≥18 years) with PCR-confirmed SARS-CoV-2 infection requiring supplemental oxygen.

Identification of biomarkers may guide treatment decisions and prognostication.

Clinical Scorecard: Comprehensive Transcriptomic and Immune Profiling Identifies Unique Mitochondrial and Immune Signatures in COVID-19 Related ARDS Necessitating Invasive Mechanical Ventilation